I-O Drugs: Key to the Cancer Moonshot?
Please complete the form below to view the webinar recording.
Checkpoint inhibitor immuno-oncology (I-O) treatments, widely considered as one the most promising breakthroughs in drug development, are a focus of the Cancer Moonshot initiative. But are these new therapies getting reimbursed and what are the challenges they face in gaining market access?
This webinar takes a data-driven look at the key challenges facing I-O drugs including:
- Cost and value
- Interpretation of clinical efficacy evidence
- Restrictions issued by HTA agencies